Using Applied BioMath Assess to Predict Doses and Align Stakeholders

Assess supports stakeholder alignment by predicting doses early in the drug development process. Potential tradeoffs between target properties, drug properties, and therapeutic concept can be identified early. Stakeholders can make informed decisions based on early understandings of risk in being able to discover a lead candidate, and manufacture it.

This case study introduces basic Assess concepts and goes through a simple dose prediction workflow for a hypothetical monoclonal antibody product. Dosing challenges are identified for a subset of patient parameters, and strategies to overcome them are explored by running a set of rapid "what if" scenarios.